Interleukin-2 inhibitors in autoimmune disease

Bibliography

• BRANDHUBER BJ, BOONE T, KENNEY WC, MCKAY DB:Three-dimensional structure of interleukin-2. Science (1987) 238: 1707-1709.
   Google Scholar
• MORGAN DA, RUSCETTI FW, GALLO R: Selective in vitrogrowth of T-lymphocytes from normal human bone marrow. Science (1976) 193:1007–1008.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI T, MATSUI H, FUJITA T et al.: Structure andexpression of a cloned cDNA for human interleukin-2. Nature (1983) 302:305–310.
   PubMed Web of Science ®Google Scholar
• JU G, COLLINS L, KAFFKA KL et al.: Structure-functionanalysis of human interleukin-2. Identification of amino acid residues required for biological activity. J. Biol. Chem. (1987) 262:5723–5731.
   Google Scholar
• HENNEY CS, KURIBAYASHI K, KERN DE, GILLIS S:Interleukin-2 augments natural killer cell activity. Na-ture (1979) 291:335–338.
   Web of Science ®Google Scholar
• ORTALDO JR, MASON AT, GERARD JP et al: Effects ofnatural and recombinant IL-2 on regulation of IFN pro-duction and natural killer activity: lack of involvement of the TAC antigen for these immunoregulatory ef-fects. J. Immunol. (1984) 133:779–783.
   PubMed Web of Science ®Google Scholar
• PIKE BL, RAUBITSCHEK A, NOSSAL GJV: Human inter- leukin 2 can promote the growth and differentiation of single hapten-specific B cells in the presence of spe-cific antigen. Proc. Natl. Acad. ScL USA (1984) 81:7917–7921.
   PubMed Web of Science ®Google Scholar
• MINGARI MC, GEROSA F, CARRA G: Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature (1984) 312:641–643.
   PubMed Web of Science ®Google Scholar
• MIZEL SB: The interleukins. FASEBJ (1989) 3:2379–2388.
   PubMed Web of Science ®Google Scholar
• TJIAN R, MANIATIS T: Transcriptional activation: a com-plex puzzle with few easy pieces. Cell (1994) 77:5–8.
   PubMed Web of Science ®Google Scholar
• MANNING AM, LEWIS AJ: Transcription factors, rheu-matoid arthritis and the search for improved antirheu-matic agents. Rheum. Arthr. (1997) 1:65–73.
   Google Scholar
• FUJITA T, SHIBUYA H, OHASHI TYAMANISHI K, TANIGUCHI T: Regulation of human interleukin-2 gene: functional DNA sequences the 5'-flanking region for the gene expression in activated T lymphocytes. Cell (1986) 46:407–410.
   Web of Science ®Google Scholar
• DURAND DB, BUSH MR, MORGAN JG, WEISS A, CRAB-TREE GR: A 275 bp fragment at the 5'-end of the IL-2 gene enhances the expression from a heterologous promoter in response to signals from the T cell anti-gen receptor. J. Exp. Med. (1987) 165:395–407.
   PubMed Web of Science ®Google Scholar
• TAKESHITA T, ASAO H, OHTANI K et al: Cloning of the y-chain of the human 11-2 receptor. Science (1992) 257:379–382.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI T: Cytokine signalling through nonrecep-tor protein tyrosine kinases. Science (1995) 268:251–255.
   PubMed Web of Science ®Google Scholar
• KARNITZ LM, BURNS LA, SUTOR SL BLENIS J, ABRAHAM RT: Interleukin-2 triggers a novel phosphatidylinositol 3-kinase dependent MEK activation pathway. MM. Cell. Biol. (1995) 15:3049–3057.
   Web of Science ®Google Scholar
• THEZE J, ALZARI P, BERTOGLIO J: Interleukin-2 and its receptors: recent advances and new immunological functions. Immunol. Today (1996) 17:481–486.
   PubMedGoogle Scholar
• AUGUSTINE JA, SUTOR SL, ABRAHA RT: Interleukin-2 and polyomavirus middle T antigen-induced modifica-tion of phosphatidylinositol 3-kinase activity in acti-vated T lymphocytes. Mol. Cell. Biol (1991) 11:4431–4440.
   PubMed Web of Science ®Google Scholar
• REMILLARD B, PETRILLO R, MASLINSKI W: Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J. Biol. Chem. (1991) 266:14167–14170.
   PubMed Web of Science ®Google Scholar
• MERIDA I, DIEZ E, GAULTON GN: 11-2 binding activates a tyrosine-phosphorylated phosphatidylinosito1-3-kinase. j Immunol (1991) 147:2202–2207.
   PubMed Web of Science ®Google Scholar
• GESBERT F, GARBAY C, BERTOGLIO J: Interleukin-2stimulation induces tyrosine phosphorylation of p120-Cbl and CrkL and formation of multimolecular signaling complexes in T lymphocytes and natural kil-ler cells. J. Biol. Chem. (1998) 273:3986–3993.
   PubMed Web of Science ®Google Scholar
• BRANDHUBER BJ, BOONE T, KENNEY WC, MCKAY DB:Three-dimensional structure of interleukin-2. Science (1987) 238: 1707-1709.
   Google Scholar
• BOREL JF, FEURER C, GUBLER HU, STAHELIN H: Biologi-cal effects of cyclosporin A: a new antilymphocyte agent. Agents Action (1976) 6:468–475.
   PubMedGoogle Scholar
• SIGAL NH, DUMONT FJ: Cyclosporin A FK506, and Ra-pamycin: pharmacologic probes of lymphocyte signal transduction. Ann. Rev. Immunol (1992) 10:519–560.
   PubMed Web of Science ®Google Scholar
• ••A good review article.
   Google Scholar
• RAO A, LUO C, HOGAN PG: Transcription factors of the NFAT family: regulation and function. Ann. Rev. Immu-nol (1997) 15:707–747.
   PubMed Web of Science ®Google Scholar
• BENNETT WM: The nephrotoxicity of immunosuppres-sive drugs. Clin. Nephrol (1995) 43:3–7.
   Web of Science ®Google Scholar
• ••This review article discuses the nephrotoxicity caused byCsA and FK506.
   Google Scholar
• KINO T, HATANAKA H, HASHIMOTO M et al.: FK-506, anovel immunosuppressant isolated from a Streptomy-ces. I. Fermentation, isolation, physico-chemical and biological characteristics. J. Antibiot. (1987) 40:1249–1255.
   Google Scholar
• THOMSON AW: FK-506 enters the clinic. Immunol. To-day (1990) 11:35–36.
   PubMedGoogle Scholar
• DUMONT FJ, STARUCH MJ, KOPRAK SL, MELINO MR, SI-GAL NH: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK506 and rapamycin. J. Immunol (1990) 144:251–258.
   PubMed Web of Science ®Google Scholar
• BRUNN GJ, HUDSON CC, SEKULIC A: Phosphorylation of the translational repressor PHAS-1 by the mammal-ian target of rapamycin. Science (1997) 277:99–101.
   PubMed Web of Science ®Google Scholar
• FESIK SW, GAMPE RJ, HOLZMAN TF et al.: Isotope-edited NMR of cyclosporin A bound to cyclophilin. Evidence for a trans 9, 10 amide bond. Science (1990) 250:1406–1409.
   Google Scholar
• BARTLETT RR, CAMPION G, MUSIKIC P et al.: Leflu-nomide: a novel immunomodulating drug. In: Nonster-oidal Anti-inflammatory Drugs. Lewis AJ, Furst DE (Eds.), Marcell Dekker, Inc., New York, USA (1994):349–366.
   Google Scholar
• BRAZELTON TR, MORRIS RE: Molecular mechanism of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophe-nolate mofetil and leflunomide. Current Opin. Immunol (1996) 8:710–720.
   PubMed Web of Science ®Google Scholar
• ••Excellent review article which discusses the details of mo-lecular mechanisms of drug action.
   Google Scholar
• LANG R, WAGNER H, HEEG K: Differential effects of theimmunosuppressive agents cyclosporine and leflu-nomide in vivo. Leflunomide blocks clonal T cell ex-pansion yet allows production of lymphokines and manifestation of T cell mediated shock. Transplantation (1995) 59:382–389.
   Google Scholar
• NIKCEVICH DA, FINNEGAN A, CHONG AS, WILLIAMS JW,BREMER EG: Inhibition of interleukin-2 stimulated ty-rosine kinase activity by leflunomide. Agents Actions (1994) 41:279–282.
   Google Scholar
• CHERWINSKI HM, MCCARLEY D, SCHATRZMAN R, DE-VENS B, RANSON JT: The immunosuppressant leflu-nomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J. Pharmcol. Exp. Ther. (1995) 272:460–468.
   Google Scholar
• •This paper describes the effect of leflunomide on cell cycle, proliferation and signal transduction events.
   Google Scholar
• WILLIAMSON RA, YEA CM, ROBSON PA et al.: Dihydro- °rotate dehydrogenase is a high affinity binding pro-tein for A771726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. (1995) 270:22467–22472.
   PubMed Web of Science ®Google Scholar
• DAVIS JP, CAIN GA, PITTS WJ, MAGOLDA RL, COPELANDRA: The immunosuppressive metabolite of Leflu-nomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry (1996) 35:1270–1273.
   PubMed Web of Science ®Google Scholar
• JACKSON RC, WEBER G: IMP dehydrogenase, an en-zyme linked with proliferation and malignancy. Na-ture (1975) 256:331–333.
   PubMed Web of Science ®Google Scholar
• NATSUMEDA Y, OHNO S, KAWASAKI H: Two distinct cDNA for human IMP dehydrogenase. J. Biol. Chem. (1990) 265:5292–5295
   PubMed Web of Science ®Google Scholar
• RANSOM JT: Mechanism of action of the immunosup-pressant prodrug mycophenolate mofetil. Ther. Drug Monit. (1995) 17:681–684.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: The IL-211L-2 receptor system: a target for rational immune intervention. Immunol. Today (1993) 14:264–270.
   PubMedGoogle Scholar
• •Excellent review article.
   Google Scholar
• MASLINSKI WB, REMILLARD B, TSUDO M, STROM TB: Interleukin-2 (IL-2) induces tyrosine kinase-dependent translocation of active raf-1 from the IL-2 receptor into the cytol. j Biol. Chem. (1992) 267:15281–15284.
   PubMed Web of Science ®Google Scholar
• FREED E, SYMONS M, MACDONALD SG, MCCORMICK F,RUGGIERI R: Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science (1994) 265: 1713-1716.
   Google Scholar
• IRIE K, GOTOH Y, YASHAR BM et al.: Stimulatory effects of yeast and mammalian 14-3-3 proteins on the Raf protein kinase. Science (1994) 265: 1716-1719.
   Google Scholar
• HAKIMI J: Humanized anti-IL-2 receptor antibodies in transplantation and autoimmunity. Immune Modula-tion for Transplantation and Autoimmune Diseases. San Francisco, CA USA (September 17–19, 1997).
   Google Scholar
• LINSLEY PS, LEDBETTER JA: The role of the CD28 recep-tor during T cell responses to antigen. Ann. Rev. Immu-not. (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• HATHCOCK KS, LASZLO G, DICKLER HB et al.: Identifica-tion of an alternative CTLA-4 ligand costimulatory for T cell activation. Science (1993) 262:905–907.
   PubMed Web of Science ®Google Scholar
• TURKA LA, LINSLEY PS, LIN H et al: T-cell activation bythe CD28 ligand B7 is required for cardiac allograft re-jection in vivo. Proc. Natl. Acad. Sci. USA (1992) 89:11102–11105.
   Google Scholar
• MORELAND LW, HECK LW, KOOPMAN WJ: Biologic agents for treating rheumatoid arthritis. Arthr. Rheum. (1997) 40:397–409.
   PubMed Web of Science ®Google Scholar
• ARMITAGE, RJ, FANSLOW WC, STROCKBINE LS et al: Mo-lecular and biological characterization of a murine ligand for CD40. Nature (1992) 357:80–82.
   PubMed Web of Science ®Google Scholar
• CAYABYAB M, PHILLIPS JH, LANIER LL: CD40 preferen-tially costimulates activation of CD4+ T lymphocytes. J. Immunol (1994) 152:1523–1531.
   PubMed Web of Science ®Google Scholar
• LARSEN CP, ALEXANDER DZ, HOLLENBAUGH DZ et al. CD40-gp39 interactions play a critical role during allo-graft rejection: Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation (1996) 61:4–9.
   PubMed Web of Science ®Google Scholar
• JY W, FREGIEN N, BOURGUIGNON GJ: Role of Ca2+ in the regulation of hormone receptor exposure during lym-phocyte activation. Biochem. Biophys. Acta (1989) 983:153–160.
   PubMed Web of Science ®Google Scholar
• CUNG SC, MCDONALD TV, GARDNER P: Inhibition bySK&F 96365 of Ca2+ current, 11-2 production and acti-vation in T-lymphocytes. Br. J. Pharmacol (1994) 113:861–868.
   PubMed Web of Science ®Google Scholar
• MERRITT JE, ARMSTRON WP, BENHAM CD et al: SK&F96365, a novel inhibitor of receptor-mediated Ca2+ en-try. Biochem. 1 (1990) 271:515-522.
   Google Scholar
• DECOURSEY TE, CHANDY KG, GUPTA S, CHAHLAN MD:Voltage-gated potassium channels in human T lym-phocytes: a role in mitogenesis? Nature (1984) 307:465–468.
   PubMed Web of Science ®Google Scholar
• MATTESON DR, DEUTSCH C: Potassium channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature (1984) 307:468–471.
   PubMed Web of Science ®Google Scholar
• KATH JC, HANSON DC, CHANDY KG: T Lymphocyte po-tassium channel blockers. In: Annual Reports in Medici-nal Chemistry. Bristol JA (Ed.), Academic Press, New York, USA (1997).
   Google Scholar
• MICHNE WF, GUILES JW, TREASURYWALA AM: Novel in-hibitors of potassium ion channels on human T lym-phocytes. J. Med. Chem. (1995) 38:1877–1883.
   PubMed Web of Science ®Google Scholar
• BURGESS LE, KOCH K, COOPER K et al.: The SAR of UK-78282: a novel blocker of human T cell Kv1.3 potas-sium channels. Bioorg. Med. Chem. Lett. (1997) 7:1047–1052.
   Google Scholar
• SULLIVAN RW, BIGAM CB, ERDMAN PE et al.: 2-Chloro-4 - (trifluor °methyl) pyrimidine-5-N- (3',5'- bis(tri-fluoromethyl) phenyl-carboxamide: a potent inhibitor of NF-KB and AP-1 mediated gene expression identified using solution-phase combinatorial chemistry. J. Med. Chem. (1998) 41:413–419.
   PubMed Web of Science ®Google Scholar
• GOLDMAN ME, RANSONE LJ, ANDERSON DW et al.: 5P100030 is a novel T-cell specific transcription factor inhibitor that possesses immunosuppressive activity in vivo. Trans. Proc. (1996) 28:3106–3109.
   Google Scholar
• PALANKI MSS, ERDMAN PE, SUTO MJ et al.: Second gen-eration inhibitors of NF-KB and AP-1 gene expression: structure-activity studies of 2-trifluoromethyl-pyrimidine-4-citraconamide-5-carboxylate. 26th Na-tional Medicinal Chemistry Symposium. Richmond, USA (1998). Abstract No. C–4.
   Google Scholar
• KUROMITSU S, FUKUNAGA M, LENNARD AC, MASUHO Y, NAKADA S: 3-(13-Hydroxytridecy0-1413-(3-pyridyfitridecyllpyridinium chloride (YM-53792), a novel inhibitor of NF-AT activation. Biochem. Pharma-col. (1997) 54:999–1005.
   PubMed Web of Science ®Google Scholar
• DUDLEY DT, PANG L, DECKER SJ, BRIDGES AJ, SALTIEL AR: A synthetic inhibitor of the mitogen-activated pro-tein kinase cascade. Proc. Natl. Acad. Sci. USA (1995) 92:7686–7689.
   PubMed Web of Science ®Google Scholar
• FAVATA MF, HORIUCHI KY, MANOS EJ et al: Identifica-tion of a novel inhibitor of mitogen-activated protein kinase. Bic)]. Chem. (1998) 273:18623–18632.
   Google Scholar